Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Clinical Breast Cancer - United States
doi 10.1016/j.clbc.2013.09.003
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Phase II Study of Pembrolizumab and Capecitabine for Triple Negative and Hormone Receptor-Positive, HER2−negative Endocrine-Refractory Metastatic Breast Cancer

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2020English

Phase II Trial of Exemestane in Combination With Fulvestrant in Postmenopausal Women With Advanced, Hormone-Responsive Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2012English

Phase 1b Study of Orteronel in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic Breast Cancer

Investigational New Drugs
OncologyPharmacology
2016English

Quantitative ER and PgR Assessment as Predictors of Benefit From Lapatinib in Postmenopausal Women With Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2013English

Phase I Trial of Exemestane in Combination With Metformin and Rosiglitazone in Nondiabetic Obese Postmenopausal Women With Hormone Receptor–positive Metastatic Breast Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2012English

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer

Frontiers in Oncology
Cancer ResearchOncology
2018English

Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor–Positive, HER2-Negative Early Breast Cancer

JAMA Oncology
Cancer ResearchOncology
2018English

A Randomized Trial of Combination Anastrozole Plus Gefitinib and of Combination Fulvestrant Plus Gefitinib in the Treatment of Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer

Breast Cancer Research and Treatment
Cancer ResearchOncology
2012English

TBCRC 002: A Phase II, Randomized, Open-Label Trial of Preoperative Letrozole With or Without Bevacizumab in Postmenopausal Women With Newly Diagnosed Stage 2/3 Hormone Receptor-Positive and HER2-negative Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy